CHRONIC FATIGUE SYNDROME Q&A

What is it? Why is it so common?What causes it? Are there treatments?DrA will discuss these and more questions on the podcast!*** ALL THINGS DrA: www.DrAnow.com =============================================================https://bestpractice.bmj.com/topics/en-us/277 https://www.ncbi.nlm.nih.gov/books/NBK557676/ ============================================================= The Common Threads of Fibromyalgia and Chronic Fatigue SyndromeMore than half of people diagnosed with fibromyalgia fit the bill for chronic fatigue syndrome, too. Are they really just the same disease?By Dennis Thompson Jr & Medically Reviewed by Lindsey Marcellin, MD, MPHReviewed: November 23, 2011https://www.everydayhealth.com/fibromyalgia/fibromyalgia-and-chronic-fatigue-syndrome.aspx=========================================================== Delay of British chronic fatigue syndrome guidelines is a setback for people with long CovidBy David Tuller and Steven Lubet, Aug. 22, 2021https://www.statnews.com/2021/08/22/delay-british-chronic-fatigue-guidelines-setback-for-me-cfs-long-covid/ https://www.nice.org.uk/guidance/ng206/documents/draft-guideline ================================================================== Sep 02, 2021 BURLINGAME, Calif., Sept. 2, 2021 /PRNewswire/ -- “Cortene Inc. announces publication of its InTiME clinical trial in which a short subcutaneous infusion of its experimental drug, CT38, achieved sustained symptom improvement in ME/CFS. The company intends to test CT38 in Long Covid, the post-acute stage of COVID-19 infection, which is considered by many to be the latest trigger for ME/CFS.Cortene believes the CRFR2 pathway is upregulated and therefore overactive, leading to the wide variety of symptoms in ME/CFS. "The conventional approach would be to block the overactive pathway," said Sanjay Chanda, PhD, Cortene's Chief Development Officer. "Instead, our counterintuitive approach seeks to overstimulate CRFR2, causing it to downregulate, without the need for chronic treatment."CT38 was subcutaneously infused at one of four infusion rates for a maximum of 10.5 hours, in 14 ME/CFS patients. CT38 treatment was safe and generally well-tolerated. It was associated with significant reduction in mean 28-day, total daily symptom score (TDSS), which aggregated 13 patient-reported, daily symptom scores. At an infusion rate of 0.03 μg/kg/h, mean TDSS improved by 26% (p less than 0.01, n = 7).”QUOTE: https://www.biospace.com/article/releases/clinical-trial-provides-preliminary-evidence-of-a-cure-for-myalgic-encephalomyelitis-chronic-fatigue-syndrome-me-cfs-and-long-covid STUDY: https://www.frontiersin.org/articles/10.3389/fnsys.2021.698240/full======================================================= DrA Research methylation and CFS https://www.academia.edu/11813721/MTHFR_in_the_CFS-FMS_Patient_Population_Incidence_and_therapy